The effect of Telbivudine therapy in patients with decompensated cirrhosis caused by HBV

Objective To study the therapeutic efficacy of telbivudine in patients with decompensated cirrhosis resulting from chronic hepatitis B.Methods A total of 64 patients were divided into two groups,group one patients(n = 34) were received telbivudine 600mg and group two patients(n = 30) were treated with Lamivudine 100mg,orally per day for 48 weeks.The changes were observed at different times including virological and biochemical markers,PT and Child-Pugh score after antiviral therapy.Results In the telbivudine group,the mean serum HBV DNA level was(5.35 ± 0.58) log10 copies/ml,and the mean serum HBV DNA levels were(1.88 ± 0.84),(2.11 ± 0.84),(2.17 ± 0.74) and(2.36 ± 0.57) log10 copies/ml at 12,24,36 and 48 weeks,respectively.The mean reductions in serum HBV DNA levels were significantly greater in telbivudine group than lamivudine group(P 0.05).After 24 weeks of therapy ALT,AST,albumin,total bilirubin and Child-Pugh scores were improved in the telbivdine group(P 0.05).Conclusion Telbivudine rapidly and effectively inhibits the replication of HBV in cirrhosis resulting from chronic hepatitis B after 48-weeks of treatment and the reduction in the level of HBV DNA also improves the liver function,PT and Child-Pugh score.